PMID- 7821177
OWN - NLM
STAT- MEDLINE
DCOM- 19950216
LR  - 20211203
IS  - 0149-5992 (Print)
IS  - 0149-5992 (Linking)
VI  - 17
IP  - 11
DP  - 1994 Nov
TI  - Human leukocyte antigen class II polymorphisms and genetic susceptibility of IDDM 
      in Egyptian children.
PG  - 1341-4
AB  - OBJECTIVE: To analyze the association between human leukocyte antigen (HLA) and 
      insulin-dependent diabetes mellitus (IDDM) in the Egyptian population for the 
      first time and, thus, to determine the frequency of risk-associated alleles 
      identified by a genomic HLA class II typing. Egyptians are genetically classified 
      as North Africans and considered to be between Caucasoids and Africans (closer to 
      Caucasoids). RESEARCH DESIGN AND METHODS: HLA class II typing was performed for 
      50 IDDM patients and 50 healthy control subjects by a restriction fragment-length 
      polymorphism (RFLP) technique. The analysis of position 57 of the DQB1 molecules 
      was conducted by polymerase chain reaction and specific sequence oligonucleotide 
      hybridization. RESULTS: The frequency of DRB1*0301-DRB3*0201-DQA1*0501-DQB1*0201 
      haplotype was 43.9% in the IDDM patients and 7.1% in the control subjects (P < 
      0.00001), reflecting the increased prevalence of DQA1*0501 susceptibility allele 
      coding for arginine (Arg) in position 52 and DQB1*0201 susceptibility allele 
      non-coding aspartic acid (Asp) at position 57. Alleles DQB1*0601 and 0603, both 
      carrying Asp at position 57 of the beta-chain, and DQA1*0103, encoding a non-Arg 
      52 alpha-chain, were significantly decreased among the IDDM patients. The 
      presence of four susceptibility residues (two DQA1 Arg 52+ and two DQB1 Asp 57-) 
      conferred the highest relative risk at 20.2. On the other hand, homozygous 
      genotypes for DQA1 non-Arg 52 and DQB1 Asp 57 were found only in the control 
      group. CONCLUSIONS: IDDM susceptibility and resistance in the Egyptian population 
      is strongly associated with the expressed DQ alpha- and beta-heterodimers in a 
      dose-effective manner, as already defined in many different ethnic groups.
FAU - Gaber, S A
AU  - Gaber SA
AD  - Italian Hospital Umberto I, Turin.
FAU - Mazzola, G
AU  - Mazzola G
FAU - Berrino, M
AU  - Berrino M
FAU - Canale, L
AU  - Canale L
FAU - Cornaglia, M
AU  - Cornaglia M
FAU - Ghali, I
AU  - Ghali I
FAU - Sergio Curtoni, E
AU  - Sergio Curtoni E
FAU - Amoroso, A
AU  - Amoroso A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diabetes Care
JT  - Diabetes care
JID - 7805975
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Alleles
MH  - Child
MH  - Diabetes Mellitus, Type 1/*genetics
MH  - Disease Susceptibility
MH  - Egypt
MH  - Female
MH  - Gene Frequency
MH  - Haplotypes
MH  - Histocompatibility Antigens Class II/analysis/*genetics
MH  - Humans
MH  - Male
MH  - Polymerase Chain Reaction
MH  - *Polymorphism, Genetic
MH  - Polymorphism, Restriction Fragment Length
MH  - Racial Groups
EDAT- 1994/11/01 00:00
MHDA- 1994/11/01 00:01
CRDT- 1994/11/01 00:00
PHST- 1994/11/01 00:00 [pubmed]
PHST- 1994/11/01 00:01 [medline]
PHST- 1994/11/01 00:00 [entrez]
AID - 10.2337/diacare.17.11.1341 [doi]
PST - ppublish
SO  - Diabetes Care. 1994 Nov;17(11):1341-4. doi: 10.2337/diacare.17.11.1341.